How Is Alexion Pharmaceuticals Positioned after 1H17?
Alexion’s revenue trends
In 2Q17, Alexion Pharmaceuticals (ALXN) generated revenues of ~$912 million, which was ~21% higher YoY (year-over-year) and ~5% higher QoQ (quarter-over-quarter). In 1H17, Alexion reported revenues of ~$1.78 billion, compared with $1.45 billion in 1H16.
In 1H17, Alexion reported net income of ~$335 million, compared with $212 million in 1H16. In 2Q17, Alexion generated net income of ~$165 million, compared with $120 million in 2Q16. Soliris and Strensiq pushed revenue growth in 2Q17, rising ~16% and ~84%, respectively, YoY.
Interested in ALXN? Don't miss the next report.
Receive e-mail alerts for new research on ALXN
In 2Q17, ALXN reported diluted earnings per common share of $0.73, compared with $0.53 in 2Q16. In 1H17, it reported diluted earnings per common share of $1.49, compared with $0.94 in 1H16.
2Q17 and 1H17 expenses
In 2Q17, Alexion reported a cost of sales of $84 million, compared with $60 million in 2Q16. It reported R&D (research and development), and SG&A (selling, general, and administrative) expenses of ~$199 million and $265 million in 2Q17, respectively, compared with $180 million and $232 million, respectively, in 2Q16.
In 1H17, ALXN reported a cost of sales, R&D expenses, and SG&A expenses of ~$153 million, ~$418 million, and ~$527 million, respectively, compared with $119 million, $356 million, and $465 million, respectively, in 1H16.
Kanuma revenue trends
In 2Q17, ALXN’s Kanuma generated revenues of ~$15 million, compared with $7 million in 2Q16. In 2Q17, Kanuma rose ~25% QoQ.
Notably, the iShares Nasdaq Biotechnology ETF (IBB) has ~3.96% of its total portfolio holdings in ALXN.